ABTB1 modulates EGFR signaling and confers icotinib sensitivity in lung adenocarcinoma

Abstract Background Icotinib is a first-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) widely used in the treatment of EGFR-mutant lung adenocarcinoma (LUAD). However, heterogeneous responses and the development of resistance limit durable clinical benefit. The mo...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Si-Yang Li, Lu Xia, Peng Xu, Gen-hong Li, Bing-chun Yang, Jing-Xun Wu, Fu-Xing Zhang, Jia-Bian Lian
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2026-04-01
Edice:	Respiratory Research
Témata:	Lung adenocarcinoma Icotinib EGFR signaling ABTB1 Drug sensitivity CRISPR–Cas9 screening
On-line přístup:	https://doi.org/10.1186/s12931-026-03682-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!